Literature DB >> 27340210

Differential Binding Activity of TGF-β Family Proteins to Select TGF-β Receptors.

Ashraf M Khalil1, Hyna Dotimas1, Julius Kahn1, Jane E Lamerdin1, David B Hayes1, Priyanka Gupta1, Michael Franti2.   

Abstract

Growth differentiation factor-11 (GDF11) and myostatin (MSTN) are highly related transforming growth factor-β (TGF-β) ligands with 89% amino acid sequence homology. They have different biologic activities and diverse tissue distribution patterns. However, the activities of these ligands are indistinguishable in in vitro assays. SMAD2/3 signaling has been identified as the canonical pathway for GDF11 and MSTN, However, it remains unclear which receptor heterodimer and which antagonists preferentially mediate and regulate signaling. In this study, we investigated the initiation and regulation of GDF11 and MSTN signaling at the receptor level using a novel receptor dimerization detection technology. We used the dimerization platform to link early receptor binding events to intracellular downstream signaling. This approach was instrumental in revealing differential receptor binding activity within the TGF-β family. We verified the ActR2b/ALK5 heterodimer as the predominant receptor for GDF11- and MSTN-induced SMAD2/3 signaling. We also showed ALK7 specifically mediates activin-B signaling. We verified follistatin as a potent antagonist to neutralize both SMAD2/3 signaling and receptor dimerization. More remarkably, we showed that the two related antagonists, growth and differentiation factor-associated serum protein (GASP)-1 and GASP2, differentially regulate GDF11 (and MSTN) signaling. GASP1 blocks both receptor dimerization and downstream signaling. However, GASP2 blocks only downstream signaling without interference from receptor dimerization. Our data strongly suggest that physical binding of GDF11 (and MSTN) to both ActR2b and ALK5 receptors is required for initiation of signaling.
Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27340210     DOI: 10.1124/jpet.116.232322

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  11 in total

Review 1.  Activin receptor-like kinases: a diverse family playing an important role in cancer.

Authors:  Holli A Loomans; Claudia D Andl
Journal:  Am J Cancer Res       Date:  2016-11-01       Impact factor: 6.166

2.  Activin and Nodal Are Not Suitable Alternatives to TGFβ for Chondrogenic Differentiation of Mesenchymal Stem Cells.

Authors:  Laurie M G de Kroon; Esmeralda N Blaney Davidson; Roberto Narcisi; Eric Farrell; Peter M van der Kraan; Gerjo J V M van Osch
Journal:  Cartilage       Date:  2016-09-07       Impact factor: 4.634

Review 3.  The influence of GDF11 on brain fate and function.

Authors:  Marissa J Schafer; Nathan K LeBrasseur
Journal:  Geroscience       Date:  2019-02-07       Impact factor: 7.713

4.  Tumor-Suppressor Inactivation of GDF11 Occurs by Precursor Sequestration in Triple-Negative Breast Cancer.

Authors:  Sameer S Bajikar; Chun-Chao Wang; Michael A Borten; Elizabeth J Pereira; Kristen A Atkins; Kevin A Janes
Journal:  Dev Cell       Date:  2017-11-20       Impact factor: 12.270

5.  Structural basis for potency differences between GDF8 and GDF11.

Authors:  Ryan G Walker; Magdalena Czepnik; Erich J Goebel; Jason C McCoy; Ana Vujic; Miook Cho; Juhyun Oh; Senem Aykul; Kelly L Walton; Gauthier Schang; Daniel J Bernard; Andrew P Hinck; Craig A Harrison; Erik Martinez-Hackert; Amy J Wagers; Richard T Lee; Thomas B Thompson
Journal:  BMC Biol       Date:  2017-03-03       Impact factor: 7.431

6.  Structural basis of specific inhibition of extracellular activation of pro- or latent myostatin by the monoclonal antibody SRK-015.

Authors:  Kevin B Dagbay; Erin Treece; Frederick C Streich; Justin W Jackson; Ryan R Faucette; Anastasia Nikiforov; Susan C Lin; Chris J Boston; Samantha B Nicholls; Allan D Capili; Gregory J Carven
Journal:  J Biol Chem       Date:  2020-02-19       Impact factor: 5.157

7.  A Sensitive and Selective Immunoassay for the Quantitation of Serum Latent Myostatin after In Vivo Administration of SRK-015, a Selective Inhibitor of Myostatin Activation.

Authors:  Shaun M Cote; Justin Jackson; Michelle Pirruccello-Straub; Gregory J Carven; Stefan Wawersik
Journal:  SLAS Discov       Date:  2019-07-26       Impact factor: 3.341

Review 8.  Candidate rejuvenating factor GDF11 and tissue fibrosis: friend or foe?

Authors:  Jan Frohlich; Manlio Vinciguerra
Journal:  Geroscience       Date:  2020-10-06       Impact factor: 7.713

Review 9.  Receptor binding competition: A paradigm for regulating TGF-β family action.

Authors:  Erik Martinez-Hackert; Anders Sundan; Toril Holien
Journal:  Cytokine Growth Factor Rev       Date:  2020-10-06       Impact factor: 7.638

10.  Blocking extracellular activation of myostatin as a strategy for treating muscle wasting.

Authors:  M Pirruccello-Straub; J Jackson; S Wawersik; M T Webster; L Salta; K Long; W McConaughy; A Capili; C Boston; G J Carven; N K Mahanthappa; K J Turner; A Donovan
Journal:  Sci Rep       Date:  2018-02-02       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.